Targeted therapy combined with neoadjuvant chemoradiotherapy for locally advanced rectal cancer

Abstract

Zhou Ning, Zhu Yuan, Luo Jialin. Targeted therapy combined with neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J]. Journal of International Oncology, 2014, 41(2): 113-116.

［1］ Huerta S. New directions in the preoperative management of adenocarcinoma of the rectum［J］. Crit Rev Oncog, 2012, 17(4)：393-396. ［2］ Hong YS, Kim DY, Lim SB, et al. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: longterm results of a Phase Ⅱ study［J］. Int J Radiat Oncol Biol Phys, 2011, 79(4)：1171-1178. ［3］ Bertolini F, Chiara S, Bengala C, et al. Neoadjuvant treatment with singleagent cetuximab followed by 5FU, cetuximab, and pelvic radiotherapy: a phase Ⅱ study in locally advanced rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2009, 73 (2)：466-472. ［4］ Velenik V, Ocvirk J, Oblak I, et al. A phase Ⅱ study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer［J］. Eur J Surg Oncol, 2010, 36(3)：244-250. ［5］ Sun PL, Li B, Ye QF. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase Ⅱ study［J］. Int J Colorectal Dis, 2012, 27(10)：1325-1332. ［6］ Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase Ⅱ clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with highrisk rectal cancer (EXPERTC)［J］. J Clin Oncol, 2012, 30(14)：1620-1627. ［7］ Kim SY, Hong YS, Kim DY, et al. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase Ⅱ study［J］. Int J Radiat Oncol Biol Phys, 2011, 81(3)：677-683. ［8］ Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX4 as firstline treatment for metastatic colorectal cancer: the OPUS study［J］. Ann Oncol, 2011, 22(7)：1535-1546. ［9］ Debucquoy A, Haustermans K, Daemen A, et al. Molecular response to cetuximab and efficacy of preoperative cetuximabbased chemoradiation in rectal cancer［J］. J Clin Oncol, 2009, 27(17)：2751-2757. ［10］ Erben P, Strbel P, Horisberger K, et al. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximabbased chemoradiotherapy in locally advanced rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2011, 81(4)：1032-1038. ［11］ Zhu Y, Liu LY, Luo JL, et al. Preoperative chemoradiation with nimotuzumab and capecitabine in patients with locally advanced rectal cancer: a phase Ⅱ study［J］. J Clin Oncol 30, 2012 (suppl: abstr e14049). ［12］ Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase Ⅰ trial results［J］. J Clin Oncol, 2006, 24(4)：656-662. ［13］ Valentini V, De Paoli A, Gambacorta MA, et al. Infusional 5fluorouracil and ZD1839 (GefitinibIressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase Ⅰ and Ⅱ Trial (1839IL/0092)［J］. Int J Radiat Oncol Biol Phys, 2008, 72(3)：644-649. ［14］田源, 蔡欣, 刘基巍. 结肠直肠癌的分子靶向治疗进展［J］. 癌症进展, 2010, 8(2)：151-155, 179. ［15］ Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase Ⅱ study［J］. J Clin Oncol, 2009, 27(18)：3020-3026. ［16］ Crane CH, Eng C, Feig BW, et al. Phase Ⅱ trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2010, 76(3)：824-830. ［17］ Nogué M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabinebased chemoradiotherapy in magnetic resonance imagingdefined poorprognosis locally advanced rectal cancer: the AVACROSS study［J］. Oncologist, 2011, 16(5)：614-620. ［18］ Velenik V, Ocvirk J, Music M, et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an openlabel phase Ⅱ study［J］. Radiat Oncol, 2011, 6：105. ［19］ Kennecke H, Berry S, Wong R, et al. Preoperative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase Ⅱ trial［J］. Eur J Cancer, 2012, 48(1)：37-45. ［20］ Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase Ⅱ trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecanrefractory colorectal cancer: the BOND2 study［J］. J Clin Oncol, 2007, 25(29)：4557-4561. ［21］ Tol J, Koopman M, Rodenburg CJ, et al. A randomised phase Ⅲ study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in firstline advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity［J］. Ann Oncol, 2008, 19(4)：734-738. ［22］ Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase ⅢB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer［J］. J Clin Oncol, 2009, 27(5)：672680. ［23］ Wong NS, Fernando NH, Nixon AB ,et al. A phase Ⅱ study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer［J］. Anticancer Res, 2011, 31(1)：255-261.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[5]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[6]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[7]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474.
[8]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing.Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer[J]. Journal of International Oncology, 2023, 50(5): 268-273.
[9]	Xu Fang, Zhu Wentian.Progress in adjuvant therapy of hepatocellular carcinoma complicated with microvascular invasion[J]. Journal of International Oncology, 2023, 50(5): 304-309.
[10]	Zeng Liwu, Du Yuqiang, Zhang Peng, Tao Kaixiong.Progress in imaging evaluation of lateral lymph node metastasis in rectal cancer[J]. Journal of International Oncology, 2023, 50(4): 248-251.
[11]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun.Construction of postoperative prognosis model for patients with colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 157-163.
[12]	Xu Liangfu, Li Yuanfei.Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 186-190.
[13]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng.Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer[J]. Journal of International Oncology, 2023, 50(12): 717-722.
[14]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu.Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer[J]. Journal of International Oncology, 2023, 50(11): 683-687.
[15]	Wang Xi, Wu Chuanqing.Research progress in reversing multidrug resistance in colorectal cancer[J]. Journal of International Oncology, 2023, 50(1): 42-46.

Targeted therapy combined with neoadjuvant chemoradiotherapy for locally advanced rectal cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments